PR PolyResearch

Join Free

NYSE

AbbVie Inc. (ABBV)

♥ 629 Thanks from members

AbbVie Inc. (ABBV) demonstrates strong Q2 2026 financial performance driven by immunology blockbusters Skyrizi and Rinvoq, offsetting Humira's decline, though investors remain split on valuation, debt levels, and the near-term dilutive impact of the Apogee Therapeutics acquisition.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Other NYSE Tickers

SK Telecom Co., Ltd. (SKM)

SEACOR Marine Holdings Inc. (SMHI)

Rayonier Inc. REIT (RYN)

Blackstone Inc. (BX)

Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor) American Depositary Shares (EDN)

Counterpoint Quantitative Equity ETF (CPAI)